Johnson And Johnson Continues To Focus On Medical Innovation
Johnson And Johnson Continues To Focus On Medical Innovation
On Wednesday, Johnson & Johnson (NYSE:JNJ) reported its second quarter results that reflected a strong momentum of its medtech and innovative medicine divisions. Although one-time charges prevented topline growth from reaching the bottom line, Johnson and Johnson showed it continues to advance its drug pipeline for a new medical era, with significant clinical milestones being attained throughout the quarter.
週三，強生公司（紐交所：JNJ）公佈了其第二季度業績，反映了其醫療技術和創新藥物部門的強勢勢頭。儘管一次性費用阻止了收入增長達到底線，但強生公司表明其繼續推進新醫療時代的藥物管線，整個季度取得了重大的臨床里程碑。
Second Quarter Highlights
二季度亮點
For the June quarter, Johnson & Johnson reported topline growth of 4.3% YoY as sales grew to $22.45 billion, surpassing the FactSet consensus of $22.33 billion. Regionally, U.S. sales grew 7.8% YoY, bringing in $12.5 billion, while international sales remained flat at $9.8 billion.
就6月季度而言，強生公司報告了4.3%的年度收入增長，銷售額增長至224.5億美元，超過FactSet的預期223.3億美元。在地區方面，美國的銷售額同比增長了7.8%，達到了125億美元，而國際銷售額保持在98億美元的水平。
Fueled by cancer drug Darzalex among other growth drivers, the innovative medicine segment recorded sales growth of 5.5%, bringing in revenue of $14.49 billion, also topping FactSet consensus of $14.12 billion.
在癌症藥物Darzalex等增長驅動因素的推動下，強生公司的創新藥物部門銷售增長了5.5%，營業收入達到了144.9億美元，也超過了FactSet的預期141.2億美元。
The medtech division grew 2.2% to $7.96 billion, coming short of Fact Set's consensus of $8.17 billion
醫療技術部門增長了2.2%，達到了79.6億美元，而Fact Set的預期爲81.7億美元。
As for Johnson & Johnson's best-selling drugs, psoriasis treatment Stelara recorded growth of 3.1% to $2.89 billion, surpassing FactSet consensus of $2.85 billion, while cancer treatment Darzalex recorded 18.4% growth with sales rising to to $2.878 billion, also slighly below the expected $2.885 billion.
至於強生公司最暢銷的藥物，治療牛皮癬的Stelara的銷售額增長了3.1%，達到了28.9億美元，超過了FactSet的預期28.5億美元，而治療癌症的Darzalex的銷售額錄得18.4%的增長，銷售額達到了28.78億美元，略低於預期的28.85億美元。
On the other hand, infectious disease drugs recorded a 13.9% drop with sales amounting to $965 million, while COVID-19 vaccine sales plummeted even more, falling 40% to $172 million.
另一方面，傳染病藥物的銷售額下降了13.9%，銷售額爲9650萬美元，而新冠疫苗的銷售額更是暴跌了40%，降至1720萬美元。
Due to one-time charges, net earnings fell almost 13% to $4.6 billion, with earnings per share dropping nearly 6% to $1.93. But adjusted for one-time items, EPS actually rose by 10.2% to $2.82.
由於一次性費用的影響，淨收入幾乎下降了13%，每股收益也下降了近6%，降至1.93美元。但在排除一次性項目後，每股收益實際上上升了10.2%，達到了2.82美元。
Slightly altered full year guidance
細微調整的全年指引
J&J raised the midpoint of its full-year guidance for operational sales from a $88.9 billion to $89.4 billion, fueled by the completion of the $13.1 billion acquisition of its newest medtech conquest, Shockwave Medical. But, due to the costs of this strategic acquisitions, it also lowered its full-year adjusted operational EPS guidance that are now expected in a range from $10 to $10.10.
強生公司將全年經營性銷售指引中點從889億美元上調至894億美元，該數字受益於新收購的醫療科技公司Shockwave Medical的131億美元收購。但由於這些戰略收購的成本，因此強生公司也將其全年經調整後的經營性每股收益指引下調到10至10.10美元的區間。
The second quarter performance reflects focus on medical innovation.
第二季度業績反映了對醫療創新的關注。
Throughout the quarter, the health care bellwether was busy with M&A. Besides completing the Shockwave deal, it scooped up bispecific antibodies biotech Proteologix for $850 million in cash. Johnson and Johnson also spent $1.25 billion to get Numab Therapeutics' experimental bispecific antibody that targets atopic dermatitis. In addition, J& J also had a few activities of the regulatory front during the quarter. Carvykti was greenlit by the Food and Drug Administration for second-line use in adults with relapsed refractory multiple myeloma, which J&J developed with Legend Biotech's. J&J also submitted an application to treat moderately to severely active Crohn's disease with Tremfya.
整個季度，這家醫療行業的風向標公司忙於進行併購。除了完成Shockwave交易外，它還以現金支付8.5億美元收購了雙特異性抗體生物技術公司Proteologix。強生公司還花費12.5億美元收購了Numab Therapeutics的試驗性雙特異性抗體，該抗體針對特應性皮炎。此外，強生在本季度還在監管方面進行了一些活動。Carvykti獲得了食品和藥品監督管理局的批准，用於治療成人復發難治性多發性骨髓瘤病患者的二線治療，該藥由傳奇生物和強生公司共同開發。強生公司還提交了一份申請，用於治療中度至嚴重活動性克羅恩病的Tremfya。
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
免責聲明：本內容僅供參考，不構成任何投資建議。
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
本文來自非報酬的外部投稿人。它不代表Benzinga的報道，並且沒有因爲內容或準確性而被編輯。
譯文內容由第三人軟體翻譯。